StockData
Rallybio Corp logo

Rallybio Corp (RLYB) stock

RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.26−0.03 (-0.20%)

Close on Nov 18, 2026Market cap $82.16MP/E 3.3Yield –

Rallybio operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Rallybio's operating cash flow for the twelve months ending Sep 30, 2026 was $30.99M. For fiscal 2025 it was -$29.81M. The highest annual figure on record is -$22.04M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$29.81M–
FY2024Dec 31, 2024-$49.28M–
FY2023Dec 31, 2023-$60.27M–
FY2022Dec 31, 2022-$57.28M–
FY2021Dec 31, 2021-$45.53M–
FY2020Dec 31, 2020-$22.04M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$2.28M–
Q2 FY2026Jun 30, 2026$45.92M–
Q1 FY2026Mar 31, 2026-$7.98M–
Q4 FY2025Dec 31, 2025-$4.68M–
Q3 FY2025Sep 30, 2025-$6.55M–
Q2 FY2025Jun 30, 2025-$8.38M–
Q1 FY2025Mar 31, 2025-$10.21M–
Q4 FY2024Dec 31, 2024-$9.86M–
Q3 FY2024Sep 30, 2024-$13.55M–
Q2 FY2024Jun 30, 2024-$10.42M–
Q1 FY2024Mar 31, 2024-$15.46M–
Q4 FY2023Dec 31, 2023-$11.65M–
Q3 FY2023Sep 30, 2023-$16.47M–
Q2 FY2023Jun 30, 2023-$13.38M–
Q1 FY2023Mar 31, 2023-$18.77M–
Q4 FY2022Dec 31, 2022-$15.26M–
Q3 FY2022Sep 30, 2022-$14.74M–
Q2 FY2022Jun 30, 2022-$13.55M–
Q1 FY2022Mar 31, 2022-$13.73M–
Q4 FY2021Dec 31, 2021-$9.89M–
Q3 FY2021Sep 30, 2021-$10.87M–
Q2 FY2021Jun 30, 2021-$12.85M–
Q1 FY2021Mar 31, 2021-$11.93M–
Q4 FY2020Dec 31, 2020-$7.26M–
Q3 FY2020Sep 30, 2020-$5.62M–

More Rallybio figures

See a number that looks wrong?